ALL Gene-Edited Cell Lines for Drug Discovery and CRISPR Models

Acute Lymphoblastic Leukemia (ALL) is a hematologic malignancy characterized by the uncontrolled proliferation of immature lymphoid cells. According to the World Health Organization (WHO) GLOBOCAN 2022, there were approximately 78,000 new cases and 34,000 deaths globally. In the United States, the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports an age-adjusted incidence rate of 1.8 per 100,000 per year, with a 5-year overall survival of 71.5% (2013-2019). Survival varies dramatically by age: 90.8% for children under 15, but only 26.2% for adults 65 and older. Key risk factors include genetic syndromes (Down syndrome, Li-Fraumeni), ionizing radiation, and certain chemotherapy exposures.

ALL is an ideal model for mechanistic studies due to its well-defined genetic subtypes, availability of large public datasets (TCGA, COSMIC, DepMap), and the ease of culturing and genetically manipulating leukemia cell lines. Open questions include mechanisms of relapse, drug resistance, and the role of clonal heterogeneity. The disease's reliance on specific oncogenic drivers (e.g., BCR-ABL1, KMT2A rearrangements) makes it a prime candidate for targeted therapy and functional genomics using gene-edited cell models.

ALL pathogenesis involves multiple disrupted pathways:

1. BCR-ABL1 Signaling (Ph+ ALL):

• • Constitutive activation of ABL1 tyrosine kinase.
• • Drives proliferation via RAS/MAPK and PI3K/AKT pathways.
• • Target of tyrosine kinase inhibitors (e.g., imatinib).

2. KMT2A (MLL) Rearrangements:

• • Chromosomal translocations (e.g., t(4;11), t(11;19)).
• • Deregulate HOX gene expression, blocking differentiation.
• • Common in infant ALL and associated with poor prognosis.

3. JAK-STAT Pathway Activation:

• • Mutations in JAK1, JAK2, or JAK3 (especially in Ph-like ALL).
• • Leads to cytokine-independent growth.
• • Often co-occurs with IKZF1 deletions.

4. Cell Cycle and Apoptosis Dysregulation:

• • CDKN2A (p16) deletions occur in ~30% of cases.
• • TP53 mutations are rare at diagnosis but enriched at relapse (~20%).
• • RB1 pathway alterations.

Data derived from TCGA (PanCancer Atlas), COSMIC (v99), and NCBI Gene.

Key signaling networks in ALL:

• • RAS-MAPK Pathway:
• • Activating mutations in KRAS, NRAS, and NF1.
• • Leads to uncontrolled cell proliferation.
• • Target for MEK inhibitors (e.g., trametinib).
• • PI3K/AKT/mTOR Pathway:
• • Activated by BCR-ABL1, JAK-STAT, or PTEN loss.
• • Promotes survival and protein synthesis.
• • Inhibitors (e.g., everolimus) in clinical trials.
• • NOTCH1 Signaling (T-ALL):
• • Mutations in NOTCH1 or FBXW7 cause constitutive activation.
• • Drives proliferation and blocks differentiation.
• • Gamma-secretase inhibitors are investigational.
• • JAK-STAT Pathway (Ph-like ALL):
• • JAK1/2/3 mutations or CRLF2 rearrangements.
• • STAT5 activation leads to gene expression changes.
• • Ruxolitinib (JAK inhibitor) is used in clinical trials.

Common ALL cell lines and their key mutations:

Organoid models for ALL are less common than for solid tumors, but patient-derived organoid cultures (PDOs) from bone marrow or peripheral blood are emerging. They preserve the genetic heterogeneity and microenvironment interactions, making them valuable for drug screening and personalized medicine.

Animal models for ALL research:

• • Patient-Derived Xenografts (PDX):
• • Engraftment of patient leukemia cells into immunodeficient mice (e.g., NSG).
• • Preserves patient-specific mutations and drug responses.
• • Used for preclinical drug testing and resistance studies.
• • Genetically Engineered Mouse Models (GEMM):
• • Examples: BCR-ABL1 transgenic, KMT2A-AF4 knock-in, NOTCH1-induced T-ALL.
• • Allow study of disease initiation and progression in vivo.
• • Induced Models:
• • Retroviral transduction of oncogenes (e.g., BCR-ABL1) into hematopoietic stem cells.
• • Followed by transplantation into irradiated recipients.
• • Faster than GEMM, but less physiological.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and point mutations. These models are essential for studying the functional impact of specific ALL-associated mutations in a controlled background.

• • Examples of gene-edited models:
• • TP53 knockout in NALM6 cells: Used to study the role of p53 in chemotherapy resistance.
• • KRAS G12D knock-in in Jurkat cells: Models RAS-driven T-ALL for drug screening.
• • NOTCH1 knockout in T-ALL lines: Validates NOTCH1 dependency and identifies resistance mechanisms.
• • IKZF1 deletion in B-ALL lines: Investigates the role of IKZF1 in B-cell differentiation and leukemogenesis.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing ready-to-use tools for functional genomics, target validation, and drug discovery. These models are typically validated by Sanger sequencing, western blot, and functional assays.

• • Gene-edited cells are used to validate the functional role of candidate oncogenes and tumor suppressors in ALL. For example:
• • Knockout of IKZF1 in B-ALL cell lines leads to impaired differentiation and increased proliferation, confirming its tumor suppressor role.
• • Knock-in of BCR-ABL1 in Ba/F3 cells creates a model for studying tyrosine kinase inhibitor (TKI) sensitivity and resistance.
• • CRISPR screens using pooled libraries in ALL cell lines identify genes essential for survival (e.g., DepMap data).

• • Isogenic cell pairs (e.g., wild-type vs. TP53 knockout) are powerful tools for drug screening:
• • TP53 knockout NALM6 cells show increased resistance to doxorubicin and etoposide, confirming p53-dependent apoptosis.
• • NOTCH1 mutant vs. wild-type T-ALL lines are used to test gamma-secretase inhibitors.
• • Resistance modeling: Chronic exposure of isogenic lines to drugs (e.g., imatinib) selects for resistant clones, revealing secondary mutations (e.g., BCR-ABL1 T315I).

• • CRISPR-based synthetic lethality screens identify new therapeutic targets and biomarkers:
• • Example: In TP53-mutant ALL cells, knockout of WEE1 or CHK1 induces synthetic lethality, suggesting these as drug targets.
• • CRISPR activation (CRISPRa) screens can identify genes that confer resistance to chemotherapy, serving as biomarkers for poor prognosis.
• • Isogenic models with specific mutations (e.g., JAK2 V617F) are used to validate candidate biomarkers from patient cohorts.